Bloodstream infections due to anaerobic bacteria in cancer patients: Epidemiology, etiology, risk factors, clinical presentation and outcome of anaerobic bacteremia

Neoplasma

Volumn 43, Issue 4, 1996, Pages 235-238

  Spanik S ^b,c   Trupl, J ^b   Kunova A ^b   Pichna, P ^a   Helpianska, L ^b   Ilavska I ^b   Kukuckova E ^a   Lacka, J ^b   Grausova S ^a   Stopkova K ^a   Drgona L ^b   Krcmery Jr V ^a,b  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

^c Heydukova 10   (Slovakia)

Author keywords

anaerobic bacteremia; cancer patients

Indexed keywords

AMIKACIN; AMPICILLIN; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN; CHLORAMPHENICOL; CLINDAMYCIN; COLISTIN; METRONIDAZOLE; OFLOXACIN; PEFLOXACIN; PENICILLIN G; QUINOLONE DERIVATIVE; TETRACYCLINE; VANCOMYCIN;

AGED; ANAEROBIC INFECTION; ARTICLE; BACTEREMIA; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; RISK FACTOR;

EID: 9544252295     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. CONBOY, K., WALAGE, L.S.: Sepsis syndrome and associated sequellae in patients at high risk for gramnegative sepsis. Pharmacoepidemiology, 15, 1995, 75-79.
2. DURAND, B., LECLERCQ, R., PIPEAU, F., DOHARVEUGT, M.C., ROCHAUT, H., ASTIER, A., DUVAL, J., CORDONNIER, C.: Evolution of bacterial susceptibility to antibiotics during a six year period in a hematology unit. J. Hosp. Inf., 29, 1995, 19-23.
3. EORTC Antimicrobial study group: Grampositive bacteremia in cancer patients from studies on empiric therapy of fever and neutropenia. Eur. J. Clin. Microbiol. Inf. Dis., 10, 1993, 366-369.
4. EORTC Antimicrobial therapy cooperative group: Amikacin plus ceftriaxone once daily versus in multiple daily doses in empiric therapy for febrile granulocytopenic patients. Ann. Inf. Med., 117, 1993, 377-382.
5. EORTC Antimicrobial therapy cooperative group: Meropenem versus ceftazidim plus amikacin in initial therapy of infections in febrile neutropenia. In: 34-th ICAAC, Orlando, Abstract No. 898.
6. EORTC Antimicrobial therapy cooperative group: Piperacillinta-zobactam plus amikacin versus ceftazidim plus amikacin in empiric therapy of febrile neutropenia in cancer patients. In: 39-th ICAAC, New Orleans, Abstract No. 1143.
7. GOLDSTEIN, E.J., CITRON, D.M.: Annual incidence, epidemiology and susceptibilities of recent isolates of Bacteroides fragilis group. J Clin. Microbiol., 26, 1988, 2361-2366.
8. GOLDSTEIN, E.J., CITRON, D.M., GOLDMAN, R.J.: National hospital survey of anaerobic culture and susceptibility testing methods. J. Clin. Microbiol., 30, 1992, 1529-1533.
9. HUGHES, W. and the IDSA ad hoc working committee: Guidelines for empiric therapy of febrile neutropenia in cancer patients. J. Inf. Dis., 33, 1990, 118-127.
10. ROSENTHAL, E.J.K.: Epidemiology of the microorganisms causing septicaemia. A multicentre blood culture study. Dtsch. Med. Wschr., 118, 1994, 1271-1290.
11. WITTMANN, D.: Intraabdominal infections. Frankfurt, Hoechst 1995, 83-85.